Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
As part of the feasibility study underway in the US ahead of the launch of the company's unique TSE (Tumour Specific Electroporation) technology, intended for the treatment of pets affected by cancer, Vetiqure AB plans to participate in a number of Veterinary Conferences during the autumn.
The feasibility study, which started during the summer and will lead to a successful launch strategy in the USA, will enter a new phase during the autumn, where vetIQure™ will be shown to a larger group of veterinarians for the first time.
Through its presence, the company wishes to introduce and demonstrate its completely new TSE technology. TSE - with its unique dynamic and safety features - aims to improve the treatment effect and at the same time reduce the unwanted destruction that sometimes occurs with the previous and static equipment.
"It will be very interesting to see how the American veterinarians receive our innovation and at the same time find out what opportunities the conferences will offer to our launch." - says Mohan Frick, CEO